(Q27021472)

page(s)

160

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

5 references

14 March 2019

21 March 2019

24 March 2019

22 April 2019

on focus list of Wikimedia project

25 April 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1750-1172-8-160

0 references

cites work

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Association between walking speed and age in healthy, free-living individuals using mobile accelerometry--a cross-sectional study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Early presentation of gait impairment in Wolfram Syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Responsiveness of the motor function measure in neuromuscular diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Toward deconstructing the phenotype of late-onset Pompe disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Gait speed and survival in older adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

A randomized study of alglucosidase alfa in late-onset Pompe's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Outcome measures in the lung

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Living with muscular dystrophy: health related quality of life consequences for children and adults

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

The natural course of non-classic Pompe's disease; a review of 225 published cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

The 6-min walk distance in healthy subjects: reference standards from seven countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Effects of scoliosis on respiratory muscle strength in patients with neuromuscular disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

24-months results in two adults with Pompe disease on enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Relationships between motor impairments and activity limitations in patients with neuromuscular disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Improvement in usual gait speed predicts better survival in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Accuracy of the actibelt(®) accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

A short and validated multiple sclerosis-specific health-related quality of life measurement for routine medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-8-160

Sniff nasal inspiratory pressure in the longitudinal assessment of young Duchenne muscular dystrophy children

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Changes in gait pattern as assessed by the GAITRite™ walkway system in MPS II patients undergoing enzyme replacement therapy

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015278

Clinical features of late-onset Pompe disease: a prospective cohort study

28 November 2018

1 reference

12 December 2020

The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis

1 reference

12 December 2020

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

1 reference

12 December 2020

Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II

1 reference

12 December 2020

Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome

1 reference

12 December 2020

Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis

1 reference

12 December 2020

Quantifying gait impairment in multiple sclerosis using GAITRite technology.

1 reference

12 December 2020

First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease

1 reference

12 December 2020

Effects of 3 weeks’ whole body vibration training on muscle strength and functional mobility in hospitalized persons with multiple sclerosis

1 reference

12 December 2020

Supine volume drop and diaphragmatic function in adults with Pompe disease

1 reference

12 December 2020

Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy

1 reference

12 December 2020

The Rasch-built Pompe-specific activity (R-PAct) scale

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients

1 reference

12 December 2020

Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease

1 reference

12 December 2020

Interpretation of treatment changes in 6-minute walk distance in patients with COPD

1 reference

12 December 2020

Identifiers

DOI

10.1186/1750-1172-8-160

1 reference